Logo

HAO

Haoxi Health Technology Limited

HAO

Haoxi Health Technology Limited • NASDAQ
$1.07 ▲ 11.46% (+0.11)
Market Cap $20.76 M
52w High $4.00
52w Low $0.09
Dividend Yield 0%
P/E 0.81
Volume 18.65K
Outstanding Shares 19.40M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q2-2025 $23.955M ▼ $607.744K ▼ $-232.533K ▼ -0.971% ▼ $-0.013 ▼ $11.612K ▼
Q4-2024 $25.016M ▲ $650.113K ▲ $529.802K ▼ 2.118% ▼ $0.042 ▼ $959.422K ▲
Q2-2024 $23.504M ▲ $383.016K ▼ $760.198K ▲ 3.234% ▲ $0.064 ▲ $829.956K ▲
Q4-2023 $19.066M ▲ $614.25K ▲ $522.706K ▲ 2.742% ▼ $0.044 $709.708K ▲
Q2-2023 $9.163M $237.634K $447.046K 4.879% $0.044 $494.496K

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q2-2025 $9.096M ▲ $22.067M ▲ $3.324M ▼ $18.743M ▲
Q4-2024 $6.656M ▲ $15.507M ▲ $4.235M ▼ $11.272M ▲
Q2-2024 $1.113M ▼ $6.175M ▲ $4.453M ▲ $1.722M ▲
Q4-2023 $1.203M ▼ $4.464M ▲ $2.898M ▲ $1.567M ▲
Q2-2023 $2.448M $2.998M $1.957M $1.041M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q2-2025 $-232.533K ▼ $-2.25M ▼ $-3.075M ▲ $7.746M ▼ $2.441M ▼ $-2.255M ▼
Q4-2024 $531.469K ▼ $-1.049M ▼ $-3.113M ▼ $9.084M ▲ $5.543M ▲ $-1.088M ▼
Q2-2024 $760.198K ▲ $301K ▲ $-16.162K ▲ $239.396K ▲ $1.113M ▲ $284.838K ▲
Q4-2023 $522.706K ▲ $-1.077M ▼ $-41.878K ▼ $-153.002K ▼ $-622.384K ▼ $-1.119M ▼
Q2-2023 $447.046K $205.038K $-3.62K $1.956M $1.077M $201.418K

Five-Year Company Overview

Income Statement

Income Statement Haoxi Health is operating at a very small scale, with revenue that has been growing but remains quite limited. Reported profit figures look flat or rounded, while earnings per share jump sharply in the most recent year, which likely reflects technical factors such as share count and accounting rather than a large, mature profit base. Overall, the income statement looks more like that of an early-stage, niche business still proving that it can generate consistent, meaningful earnings, and small changes in activity could have an outsized impact on reported results.

Balance Sheet

Balance Sheet The balance sheet appears very lean: only a small pool of assets and cash, matched by a modest level of equity and essentially no debt. This light structure suggests the company is not heavily burdened by borrowings, which reduces financial pressure, but it also means there is only a thin financial cushion if growth slows or costs rise. In practical terms, the company’s ability to fund expansion and absorb shocks may depend heavily on maintaining access to capital markets or quickly scaling its operations.

Cash Flow

Cash Flow Reported operating cash flow and free cash flow are essentially flat and close to zero across the disclosed period, which is typical for a very small or early-stage business but also makes it difficult to assess the underlying cash-generating power. This pattern suggests the company has not yet demonstrated a clear, sustained ability to turn its niche advertising services into strong, reliable cash inflows. As the business grows, the key question will be whether new contracts and services translate into stable, positive cash flow rather than just accounting earnings.

Competitive Edge

Competitive Edge Haoxi Health occupies a specialized niche: digital marketing focused on healthcare and medical aesthetics in China. Its strengths lie in industry-specific knowledge, familiarity with healthcare regulations, and deep relationships with major Chinese online platforms, combined with a “one‑stop” service model that can make it hard for clients to switch. The customized livestreaming agency for medical aesthetics and focus on short‑video formats align well with current marketing trends. However, it still competes in a crowded arena with larger generalist agencies, in‑house marketing teams at healthcare companies, and the self‑service advertising tools of the big platforms themselves, all under a regulatory environment that can be unpredictable for healthcare advertising.

Innovation and R&D

Innovation and R&D The company’s main innovation is its proprietary “Bidding Compass” software, which aims to improve how and where ads are placed by using data to optimize campaigns. Combined with its integrated offering—from planning to content production to campaign optimization—and its newer livestreaming services, Haoxi is positioning itself as a tech-enabled, full‑cycle marketing partner for healthcare clients. On the innovation front, the key watchpoints are whether it can keep meaningfully improving its software, scale livestreaming beyond a few flagship clients, and turn its campaign data into new value‑added products or partnerships. Given the company’s small size, its R&D and tech investments are likely tightly focused, so prioritization and execution quality will matter more than raw spending levels.

Summary

Haoxi Health is a young, niche digital marketing company tied to China’s healthcare and medical aesthetics sectors, with a story that is more about positioning and potential than about currently large and stable financials. The financials show small but growing revenues, a very lean balance sheet, and cash flows that have yet to clearly demonstrate a strong, self‑funding business. On the strategic side, its specialization, proprietary “Bidding Compass” tool, one‑stop service model, and move into livestreaming create a differentiated profile in a tightly regulated, fast‑moving market. Key uncertainties revolve around scale, client concentration, regulatory changes in healthcare advertising, and the company’s ability to turn its innovations and contracts into durable, cash‑generating growth over time. The recent stock split reflects a change in share structure rather than an obvious shift in the underlying business quality.